Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

BACKGROUND AND AIM: The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Quaquarini, E., D'Ambrosio, D., Sottotetti, F., Gallivanone, F., Hodolic, M., Baiardi, P., Palumbo, R., Vellani, C., Canevari, C., Bernardo, A., Castiglioni, I., Porta, C., Trifirò, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458948/
https://www.ncbi.nlm.nih.gov/pubmed/31049043
http://dx.doi.org/10.1155/2019/4325946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458948/
https://www.ncbi.nlm.nih.gov/pubmed/31049043
http://dx.doi.org/10.1155/2019/4325946

Ejemplares similares